Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
-
Publication number: 20120171244Abstract: Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.Type: ApplicationFiled: February 4, 2012Publication date: July 5, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Derek O'Hagan
-
Publication number: 20120171242Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: January 19, 2012Publication date: July 5, 2012Applicant: VACCIBODY ASInventors: Bjarne BOGEN, Agnete Brunsvik Fredriksen, Inger SANDLIE
-
Publication number: 20120171292Abstract: The disclosure relates to immunizing agents and devices.Type: ApplicationFiled: January 3, 2012Publication date: July 5, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael J. Sailor, Stephen M. Hedrick, Lou Gu, Laura Ruff, Zhengtao Qin
-
Patent number: 8206720Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.Type: GrantFiled: June 8, 2005Date of Patent: June 26, 2012Assignee: Novartis Vaccines & Diagnostics, IncInventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
-
Publication number: 20120156219Abstract: The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.Type: ApplicationFiled: February 22, 2012Publication date: June 21, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hiromu HABASHITA, Masaya KOKUBO, Shiro SHIBAYAMA, Hideaki TADA, Tatsuya TANIHIRO
-
Publication number: 20120148621Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: ApplicationFiled: June 11, 2010Publication date: June 14, 2012Applicant: VACCINE TECHNOLOGIES, INCORPORATEDInventors: Yichen Lu, Nicholas Kuchner, Amie Strong, Zhenhui Xu
-
Patent number: 8198088Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.Type: GrantFiled: August 31, 2011Date of Patent: June 12, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
-
Patent number: 8197821Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.Type: GrantFiled: February 25, 2008Date of Patent: June 12, 2012Assignee: Laboratoire BiodimInventors: Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stéphane Emiliani, Clarissa Berlioz-torrent, Guillaume Blot
-
Patent number: 8197822Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.Type: GrantFiled: August 15, 2011Date of Patent: June 12, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
-
Patent number: 8197819Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.Type: GrantFiled: June 8, 2005Date of Patent: June 12, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
-
Publication number: 20120141527Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: ApplicationFiled: June 18, 2010Publication date: June 7, 2012Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20120141526Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.Type: ApplicationFiled: October 30, 2007Publication date: June 7, 2012Applicant: The Regents of the University of MichiganInventors: James R. Baker, Anna Bielinska, Andrzej Myc
-
Publication number: 20120141465Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.Type: ApplicationFiled: October 4, 2007Publication date: June 7, 2012Applicant: La Jolla Institute for Allergy and ImmunologyInventors: MICHAEL CROFT, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware
-
Patent number: 8183352Abstract: The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.Type: GrantFiled: December 15, 2006Date of Patent: May 22, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Velpandi Ayyavoo, Thanadavarayan Nagashunmugam, David B. Weiner
-
Patent number: 8183354Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.Type: GrantFiled: November 15, 2007Date of Patent: May 22, 2012Assignee: University of Maryland, BaltimoreInventors: Anthony L. DeVico, Timothy R. Fouts, Robert G. Tuskan
-
Publication number: 20120121634Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In additon, the subject invention can be used in the prevention and/or treatment of tumor or cancer.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: The University of Hong KongInventors: ZHIWEI CHEN, Jingying Zhou
-
Publication number: 20120121635Abstract: Plants are engineered to express HIV related surface protein genes. The plants can be used as a source of the protein for a variety of purposes. Plant tissue can be orally administered to animals to elicit an immune response or provide protection from viral infection. The protein can be extracted and delivered to animals. Plant produced proteins can also provide a less expensive and more readily available source of the protein as reagents or in other experimentation involving HIV and SIV proteins.Type: ApplicationFiled: December 9, 2011Publication date: May 17, 2012Applicant: PRODIGENE, INC.Inventors: Michael Horn, Stephen Streatfiled, Joseph Jilka
-
Publication number: 20120114693Abstract: Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described are compositions comprising a mucosal adjuvant and one or more antigens derived from HIV. Also provided is the use of these gene delivery vehicles in inducing mucosal, local, and/or systemic immune responses following mucosal immunization regimes.Type: ApplicationFiled: January 12, 2012Publication date: May 10, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: MICHAEL VAJDY, JOHN POLO, THOMAS W. DUBENSKY, JR., DEREK O'HAGAN
-
Publication number: 20120114692Abstract: Immunogenic compositions containing phospholipid adjuvants, including microparticle and emulsion compositions. According to one aspect of the invention, an immunogenic microparticle composition is provided comprising: water; a polymer microparticle; an antigen adsorbed to the microparticle; and a phospholipid compound, e.g., a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a phosphato group and a phosphodiester group; (ii) a plurality of linear alkane groups. According to another aspect of the invention an immunogenic emulsion composition is provided that comprises: water; a metabolizable oil; an emulsifying agent; an antigen; and a phospholipid compound, e.g., a synthetic phospholipid compound like that above. The emulsion composition is an oil-in-water emulsion having oil and aqueous phases, in which the oil phase is in the form of oil droplets, substantially all of which are less than 1 micron in diameter.Type: ApplicationFiled: October 10, 2011Publication date: May 10, 2012Applicant: NOVARTIS AGInventor: Derek O'Hagan
-
Patent number: 8173137Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.Type: GrantFiled: October 22, 2009Date of Patent: May 8, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan Zur Megede, Susan W. Barnett
-
Patent number: 8173767Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.Type: GrantFiled: March 11, 2008Date of Patent: May 8, 2012Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Ara Hovanessian, Jean-Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
-
Publication number: 20120107354Abstract: The present invention provides a vaccine against a viral infection. The exemplary vaccine comprises a viral antigen of a vaccine strain of a virus; wherein the viral antigen is derived from a virus preparation of the vaccine strain of the virus; wherein the virus preparation of the vaccine strain of the virus contains a subpopulation of infectious viral particles, and the subpopulation of infectious viral particles is represented as a proportion over the total viral particles or total viral antigens of the virus preparation; and wherein the proportion of the subpopulation of infectious viral particles over the total viral particles or total viral antigens of the virus preparation is over a predefined threshold; so that the vaccine provides at least partial inter-subtypic or intra-subtypic cross immune response against different strains of the virus than the vaccine strain.Type: ApplicationFiled: October 22, 2011Publication date: May 3, 2012Inventor: GEORGE DACAI LIU
-
Patent number: 8168194Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.Type: GrantFiled: February 3, 2006Date of Patent: May 1, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
-
Patent number: 8168418Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.Type: GrantFiled: April 30, 2010Date of Patent: May 1, 2012Inventors: Susan W Barnett, Jan Zur Megede, Indresh Srivastava, Ying Lian, Karin Hartog, Hong Liu, Catherine Greer, Mark Selby, Christopher Walker
-
Publication number: 20120093858Abstract: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.Type: ApplicationFiled: December 23, 2011Publication date: April 19, 2012Inventor: David I. Cohen
-
Publication number: 20120093857Abstract: This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive substance is administered to produce an immunologic response that decreases intraocular pressure or has a neuro-protective effect beneficial in the treatment of glaucoma patients. The invention may also be used as a provocative test to diagnose glaucoma as well as identify those patients at risk for developing glaucoma. The invention may also be used to prevent the development of glaucoma in patients deemed to be at high risk of developing glaucoma, such as glaucoma suspects or ocular hypertensive patients.Type: ApplicationFiled: December 13, 2011Publication date: April 19, 2012Inventor: Emil William Chynn
-
Publication number: 20120087976Abstract: The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.Type: ApplicationFiled: June 8, 2010Publication date: April 12, 2012Inventors: Veronique Henderickx, Dominique Ingrid Lemoine
-
Publication number: 20120087938Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.Type: ApplicationFiled: August 23, 2011Publication date: April 12, 2012Applicants: DUKE UNIVERSITY, THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise Kothe, Ying Ying Li, Julie Decker, Hua-Xin Liao
-
Patent number: 8147840Abstract: This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.Type: GrantFiled: May 13, 2005Date of Patent: April 3, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gilad Ofek, Peter D. Kwong, Richard Wyatt, Min Tang
-
Patent number: 8147839Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.Type: GrantFiled: November 3, 2009Date of Patent: April 3, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Eva Felder
-
Patent number: 8143054Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.Type: GrantFiled: June 24, 2009Date of Patent: March 27, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Eva Felder
-
Patent number: 8137931Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.Type: GrantFiled: November 3, 2009Date of Patent: March 20, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Eva Felder
-
Patent number: 8133666Abstract: The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of a lentivirus in a cell; and methods of reducing the emergence of drug-resistant strains of lentivirus. The present invention further provides methods for treating lentivirus infections.Type: GrantFiled: October 31, 2005Date of Patent: March 13, 2012Assignee: The J. David Gladstone InstitutesInventors: Robert M. Grant, Khaoula Bourara
-
Patent number: 8133494Abstract: The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the stem region. The expression cassettes may be used, for example, to express the encoded polypeptide. A recombinant expression system for use in a selected host cell comprising an expression cassette encoding for the modified HIV-1 Env polypeptide is also described.Type: GrantFiled: March 13, 2007Date of Patent: March 13, 2012Assignee: Novartis Vaccine & Diagnostics IncInventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
-
Publication number: 20120052090Abstract: An object of the present invention is to provide an HIV antibody-inducing peptide antigen that can be used without problems for HIV, which is highly prone to mutation, and is effective in developing an antibody or a vaccine having excellent specificity and binding activity even for the three-dimensional structure of a neutralization target, i.e. the mechanism by which HIV invades a target cell; a method for synthesizing the same; a vaccine comprising the peptide antigen, or an HIV three-dimensional structure-recognizing antibody induced by the peptide antigen; and a preventive and/or therapeutic agent for HIV infection comprising the peptide antigen, the vaccine, or the HIV three-dimensional structure-recognizing antibody as an active ingredient.Type: ApplicationFiled: May 14, 2010Publication date: March 1, 2012Applicant: National University Corporation Tokyo Medical and Dental UniversityInventors: Hirokazu Tamamura, Toru Nakahara, Wataru Nomura
-
Patent number: 8124102Abstract: A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion between the endonuclease cleavage sites Nco I and Xho I.Type: GrantFiled: January 21, 2009Date of Patent: February 28, 2012Inventor: Sateesh Apte
-
Publication number: 20120045472Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.Type: ApplicationFiled: April 8, 2011Publication date: February 23, 2012Applicants: Beth Israel Deaconess Medical Center, Children's Medical Center CorporationInventors: Stephen C. Harrison, Bing Chen, Dan C. Barouch, Joseph P. Nkolola, Michael Scott Seaman
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Patent number: 8119140Abstract: The present invention relates to mosaic clade M HIV-1 Nef polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.Type: GrantFiled: August 23, 2006Date of Patent: February 21, 2012Assignees: Los Alamos Security, LLC, Beth Israel Deaconess Medical Center, Duke University, The University of Alabama at Birmingham Research FoundationInventors: Bette T. Korber, Simon Perkins, Tanmoy Bhattacharya, William M. Fischer, James Theiler, Norman Letvin, Barton F. Haynes, Beatrice H. Hahn, Karina Yusim, Carla Kuiken
-
Patent number: 8119144Abstract: The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. In a preferred embodiment, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (referred to as “GRIN”), HIV-1 Clade A Gag, RT, and Nef (referred to as (“GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including in preferred embodiment, adenovirus vectors containing such transgenes.Type: GrantFiled: June 4, 2007Date of Patent: February 21, 2012Assignee: International AIDS Vaccine InitiativeInventors: Kalpana Gupta, Nicholas Jackson
-
Publication number: 20120039923Abstract: The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.Type: ApplicationFiled: September 9, 2005Publication date: February 16, 2012Applicant: THE HENRY M. JACKSON FOUNDATIONInventors: Christopher Broder, Gerald Quinnan
-
Patent number: 8114585Abstract: The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acid in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIVs ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).Type: GrantFiled: June 12, 2007Date of Patent: February 14, 2012Assignee: Monogram Biosciences, Inc.Inventor: Wei Huang
-
Publication number: 20120034254Abstract: Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.Type: ApplicationFiled: February 6, 2009Publication date: February 9, 2012Inventors: Peter D. Kwong, Gary J. Nabel, George Shaw, William Schief, Zhi-yong Yang, Tongqing Zhou, Lei Chen, Young Do Kwon
-
Patent number: 8110192Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.Type: GrantFiled: July 24, 2009Date of Patent: February 7, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Mei-Yun Zhang
-
Publication number: 20120027798Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.Type: ApplicationFiled: July 6, 2011Publication date: February 2, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Kelly Reed Clark, Philip R. Johnson, JR.
-
Patent number: 8105600Abstract: The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention.Type: GrantFiled: October 30, 2008Date of Patent: January 31, 2012Assignee: International Aids Vaccine InitiativeInventors: Wayne C. Koff, Sanjay Phogat
-
Publication number: 20120021000Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: ApplicationFiled: July 18, 2011Publication date: January 26, 2012Applicant: UNIVERSITY OF KANSAS MEDICAL CENTERInventors: Opendra Narayan, Zhenqian Liu
-
Publication number: 20120020998Abstract: The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought into contact with peripheral blood mononuclear cells (PBMC), and cultured or injected into an organism. The pulsed and irradiated pDC and the PBMC share at least one major histocompatibility complex (MHC) allele.Type: ApplicationFiled: May 15, 2009Publication date: January 26, 2012Applicant: ETABLISSEMENT FRANCAIS DU SANGInventors: Joel Plumas, Caroline Aspord, Laurence Chaperot-Dubonnet
-
Publication number: 20120020999Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: ApplicationFiled: July 18, 2011Publication date: January 26, 2012Applicant: UNIVERSITY OF KANSAS MEDICAL CENTERInventors: Opendra Narayan, Zhenqian Liu
-
PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS
Publication number: 20120014989Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Inventors: James D. Rodgers, Haisheng Wang, Andrew P. Combs, Richard B. Sparks